Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma

BACKGROUND: Tralokinumab is an anti–interleukin (IL)-13 monoclonal antibody investigated for the treatment of severe, uncontrolled asthma in two Phase III clinical trials, STRATOS 1 and 2. The STRATOS 1 biomarker analysis plan was developed to identify biomarker(s) indicative of IL-13 activation lik...

Descripción completa

Detalles Bibliográficos
Autores principales: Gottlow, Mattis, Svensson, David J., Lipkovich, Ilya, Huhn, Monika, Bowen, Karin, Wessman, Peter, Colice, Gene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Technical Advance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637533/
https://www.ncbi.nlm.nih.gov/pubmed/31315668
http://dx.doi.org/10.1186/s12890-019-0889-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637533/
https://www.ncbi.nlm.nih.gov/pubmed/31315668
http://dx.doi.org/10.1186/s12890-019-0889-4

Ejemplares similares